References of "Beguin, Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailLIVER TRANSPLANTATION FOR ACUTE HEPATIC FAILURE DUE TO CHEMOTHERAPY-INDUCED HEPATITIS B VIRUS REACTIVATION IN LYMPHOMA PATIENTS
Noterdaeme, T.; Longree, L.; Bataille, C. et al

in Transplant International (2011, February), 24(1), 10-10

Detailed reference viewed: 35 (13 ULg)
Full Text
See detailLongitudinal Monitoring of Immune Reconstitution After Allogeneic Peripheral Blood Stem Cell Transplantation (HSCT): Impact of T Cell Depletion of the Graft
SERVAIS, Sophie ULg; Hannon, Muriel ULg; Daulne, Coline ULg et al

in Belgian Journal of Hematology (2011), Abstracts book(Supplement of 26th General Meeting of the Belgian Hematological Society), 31

Detailed reference viewed: 5 (3 ULg)
Full Text
See detailComparison of Immune Reconstitution after Non-myeloablative Hematopoietic Cell Transplantation (HCT) with Flu-TBI versus TLI-ATG Conditioning
Hannon, Muriel ULg; Humblet-Baron, S.; Graux, C. et al

in Belgian Journal of Hematology (2011), Abstracts book(Supplement of 26th General Meeting of the Belgian Hematological Society), 8

Detailed reference viewed: 11 (2 ULg)
Full Text
Peer Reviewed
See detailToo low iron doses and too many dropouts in negative iron trial
Aapro, M.; Beguin, Yves ULg; Birgegard, G. et al

in Journal of Clinical Oncology (2011)

Detailed reference viewed: 4 (0 ULg)
Full Text
Peer Reviewed
See detailLymphome du manteau : prise en charge 2011
Bonnet, Christophe ULg; CAERS, Jo ULg; DE PRIJCK, Bernard ULg et al

in Revue Médicale Suisse (2011), 7

Le lymphome du manteau (LM) représente 6% des lymphomes non hodgkiniens (LNH). Le diagnostic repose sur l'immunophénotypage et la démonstration de la présence de la location entre les chromosomes 11 et 14 ... [more ▼]

Le lymphome du manteau (LM) représente 6% des lymphomes non hodgkiniens (LNH). Le diagnostic repose sur l'immunophénotypage et la démonstration de la présence de la location entre les chromosomes 11 et 14, avec surexpression de la cycline D1. Le traitement de première ligne du sujet jeune associe trois cures de R-CHOP21 alternées avec trois cures de R-DHAP21, suivies d'une autogreffe conditionnée par irradiation corporelle totale, cyclophosphamide et aracytine. Le sujet de plus de 65 ans peut bénéficier de huit cures de R-CHOP21. L'intérêt du traitement de maintenance est en cours d'évaluation. L'allogreffe de cellules souches hématopoïétiques offre une chance de guérison aux patients en rechute en bon état général. Les traitements ciblés permettront une amélioration du pronostic de cette maladie. [less ▲]

Detailed reference viewed: 55 (4 ULg)
Full Text
Peer Reviewed
See detailReduced intensity conditioning for allogeneic hematopoietic stem cell transplantation (HSCT)
Servais, Sophie ULg; Beguin, Yves ULg; Baron, Frédéric ULg

in Belgian Journal of Hematology (2011), 2

Reduced intensity conditioning (RIC) regimens have allowed performing allogeneic haematopoietic stem cell transplantation (HSCT) in patients for whom conventional myeloablative allogeneic HSCT is ... [more ▼]

Reduced intensity conditioning (RIC) regimens have allowed performing allogeneic haematopoietic stem cell transplantation (HSCT) in patients for whom conventional myeloablative allogeneic HSCT is associated with unacceptable risks of non-relapse-mortality. This approac relies mainly on graft-versus-tumour effects for tumour eradication. Retrospective studies have suggested that, in patients aged 40 to 60 years, RIC-HSCT was associated with a higher risk of relapse but a lower incidence of transplant-related mortality than myeloablative allogeneic HSCT, leading to similar progression-free and overall survivals. After reviewing the rationale for RIC-HSCT, this article discusses the results of RIC-HSCT in specific deseases, and proposes what could be current indications for RIC-HSCT in 2011. Finally, the article briefly presents some possible strategies aimed at increasing the anti-tumoral activity of the procedure while reducing the incidence and severity of acute graft-versus-host disease. [less ▲]

Detailed reference viewed: 63 (16 ULg)
Full Text
Peer Reviewed
See detailAllogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning
SERVAIS, Sophie ULg; Baron, Frédéric ULg; Beguin, Yves ULg

in Transfusion & Apheresis Science (2011), 44

Allogeneic hematopoietic stem cell transplantation (HSCT) following myeloablative (conventional) conditioning regimen is associated with a high incidence of transplant-related morbidity and mortality ... [more ▼]

Allogeneic hematopoietic stem cell transplantation (HSCT) following myeloablative (conventional) conditioning regimen is associated with a high incidence of transplant-related morbidity and mortality, limiting its use to younger patients without medical co-morbidities. Over the past few years, it has become more evident that the alloreactivty of transplanted donor immunocompetent cells against host tumor cells (graft-versus-tumor effects, GVT effects) plays a major role in eradicating malignancies after allogeneic HSCT. Based on these observations, several groups of investigators have developed reduced intensity conditioning (RIC) regimens allowing patients who are ineligible for conventional HSCT to benefit from the potentially curative GVT effects of allogeneic transplantation. Retrospective studies have suggested that, in comparison with myeloablative allogeneic HSCT, in patient aged 40-60 years, RIC HSCT was associated with a higher risk of relapse but a lower incidence of transplant-related mortality leading to similar progression-gree and overall survivals. Prospective studies are ongoing to define which patients might most benefit from RIC HSCT, and to increase the anti-tumoral activity of the procedure while reducing the incidence and the severity of acute graft-versus-host disease (GVHD). In this article, we review the current status and perspectives of RIC HSCT. [less ▲]

Detailed reference viewed: 22 (3 ULg)
Full Text
Peer Reviewed
See detailBiological aspects of angiogenesis in multiple myeloma.
Otjacques, Eléonore ULg; Binsfeld, Marilène ULg; Noël, Agnès ULg et al

in International Journal of Hematology (2011), 94(6), 505-18

Multiple myeloma (MM) is a hematological malignancy characterized by the aberrant expansion of malignant plasma cells within the bone marrow (BM). One of the hallmarks of this disease is the close ... [more ▼]

Multiple myeloma (MM) is a hematological malignancy characterized by the aberrant expansion of malignant plasma cells within the bone marrow (BM). One of the hallmarks of this disease is the close interaction between myeloma cells and neighboring cells within the BM. Angiogenesis, through the activation of endothelial cells, plays an essential role in MM biology. In the current review, we describe the angiogenesis process in MM by identifying the interacting cells, the pro- and anti-angiogenic cytokines modulated, and the extracellular matrix degrading proteases liable to participate in the pathophysiology. Finally, we highlight the impact of hypoxia (through hypoxia-inducible factor-1) and constitutive activation of nuclear factor-κB in this tumor-induced neo-vascularization. [less ▲]

Detailed reference viewed: 31 (6 ULg)
Full Text
Peer Reviewed
See detailPrise en charge actuelle des syndromes myélodysplasiques
CAERS, Jo ULg; BONNET, Christophe ULg; GRAUX, Carlos et al

in Revue Médicale Suisse (2011), 7

Detailed reference viewed: 17 (6 ULg)
Full Text
Peer Reviewed
See detailUnrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia : a survey on behalf of Eurocord and CLWP of EBMT
Robin, M.; Sanz, G. F.; Ionescu, I. et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2011), 25

Detailed reference viewed: 12 (3 ULg)
Full Text
See detailGVHD chronique et effet anti-tumoral
Baron, Frédéric ULg; Beguin, Yves ULg

in Correspondance en Onco-Hématologie (2010), 5

It was demonstrated in 1981 that chronic GVHD was associated with a strong decrease of the relapse risk after conventional allogeneic hematopoietic cell transplantation (graf-versus-tumor effects). Recent ... [more ▼]

It was demonstrated in 1981 that chronic GVHD was associated with a strong decrease of the relapse risk after conventional allogeneic hematopoietic cell transplantation (graf-versus-tumor effects). Recent studies suggest that chronic GVHD might also been associated with improved progression-gree survival after allogeneic hematopoietic cell transplantation with reduced-intensity conditioning (RIC-allo), a transplant strategy based mainly on graft-versus-tumor effects for tumor eradication. Further, it has been demonstrated that elimination of leukemic cells after RIC-allo is due to donor T-cell cloones directed against multiple minor histocompatibility antigens (specific for the recipient) that are largely expressed not only by tumor cells but also by non-hematopoietic tissues, explaining the strong association between GVHD and graft-versus-tumor effects seen after RIC-allo. [less ▲]

Detailed reference viewed: 38 (2 ULg)